Janus Henderson Global Life Sciences S (JFNSX)

Fund Assets	5.81B
Expense Ratio	1.19%
Min. Investment	$2,500
Turnover	30.00%
Dividend (ttm)	3.51
Dividend Yield	3.98%
Dividend Growth	-5.57%
Payout Frequency	Annual
Ex-Dividend Date	Dec 5, 2025

Previous Close	88.26
YTD Return	14.62%
1-Year Return	41.58%
5-Year Return	52.85%
52-Week Low	65.08
52-Week High	88.82
Beta (5Y)	0.79
Holdings	100
Inception Date	Jul 6, 2009

About JFNSX

Janus Henderson Global Life Sciences Fund Class S is an open-ended mutual fund specializing in equities within the global life sciences sector. Its primary purpose is to provide long-term capital growth by allocating at least 80% of assets to companies with a life sciences orientation—such as those focused on healthcare, biotechnology, pharmaceuticals, medical devices, and health care services—across any market capitalization and region. The fund actively seeks companies that address unmet medical needs or aim to make health care delivery more efficient, maintaining diversification not only geographically but also across industry subsectors. It is managed by a team of healthcare and scientific specialists employing a disciplined investment and risk management process, with reference to but not limited by the MSCI World Health Care Index. The fund’s holdings typically include leading global healthcare firms and innovators, reflecting its emphasis on sectors and businesses poised to benefit from advancements in science, technology, and the evolution of healthcare systems worldwide.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: High
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: JFNSX
• Share Class: Class S
• Index: MSCI World/Health Care NR

Performance

JFNSX had a total return of 41.58% in the past year, including dividends. Since the fund's inception, the average annual return has been 15.19%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JFNIX	Class I	0.78%
JNGLX	Class D	0.81%
JAGLX	Class T	0.92%

Top 10 Holdings

41.35% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	8.86%
Johnson & Johnson	JNJ	6.92%
AstraZeneca PLC	AZN	4.39%
UnitedHealth Group Incorporated	UNH	4.30%
AbbVie Inc.	ABBV	3.92%
Revolution Medicines, Inc.	RVMD	2.96%
Novartis AG ADR	NVSN.MX	2.71%
argenx SE	ARGX	2.51%
Thermo Fisher Scientific Inc.	TMO	2.42%
Praxis Precision Medicines, Inc.	PRAX	2.35%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 5, 2025	$3.50786	Dec 5, 2025
Dec 6, 2024	$3.71459	Dec 6, 2024
Dec 7, 2023	$2.85171	Dec 7, 2023
Dec 20, 2021	$6.57436	Dec 20, 2021
Dec 17, 2020	$5.35765	Dec 17, 2020
Dec 17, 2019	$3.63608	Dec 17, 2019

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Aug 27, 2026

Data Sources Report a data error